RxDoctor Payments Data

David Kayne, MD

Internal Medicine · Encino, CANPI 1144334533

Payments from drug & device makers

$888,004in general payments, 2019–2025

Across 1,651 payments — averaging $537.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$367K
  • Novo Nordisk$184K
  • Dexcom, Inc.$87K
  • Bayer$44K
  • Xeris Pharmaceuticals, Inc.$40K
  • AbbVie$33K
  • plus $133K from 35 others

What the payments were for

  • Consulting fees$39,9575%
  • Speaking & faculty fees$686,59781%
  • Travel & lodging$78,2899%
  • Food & beverage$37,9004%
  • Education$7120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$888,004 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$326,914
Medicare patients
433
Services billed
11,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide241$300,898
OzempicSemaglutide162$237,555
JardianceEmpagliflozin90$115,744
AfrezzaInsulin Regular, Human27$105,892
FarxigaDapagliflozin Propanediol83$89,180
Tresiba Flextouch U-200Insulin Degludec67$76,086
TradjentaLinagliptin63$67,128
Repatha SureclickEvolocumab57$64,878
JanuviaSitagliptin Phosphate63$63,741
ForteoTeriparatide13$56,057
XareltoRivaroxaban45$54,166
TrulicityDulaglutide29$52,735
EliquisApixaban36$52,482
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/747$50,983
RybelsusSemaglutide34$43,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog, Lyumjev$367,258$429,405350 claims
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$183,735$305,418239 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr$81$221,829186 claims
Mannkind CorporationAfrezza$23,663$105,89227 claims
Johnson & JohnsonXarelto, Invokana$26,617$92,57087 claims
AstraZenecaFarxiga$14,193$89,18083 claims
MerckJanuvia$193$63,74163 claims
BayerKerendia$44,409$24,76322 claims
AbbVieSynthroid$32,565$11,524155 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$22,030$8,58512 claims
GSKBreo Ellipta$114$7,68119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →